Zavesca Articles
FTC files Amicus Brief, saying improper use of restricted drug distribution programs may impede generic competition
13 March 2013
Actelion buys option to acquire privately-held Trophos; posts strong 2nd-qtr 2010 results
20 July 2010
Actelion shares plunge as Tracleer fails to meet primary endpoint in idiopathic pulmonary fibrosis
2 March 2010
Soaring Tracleer sales boost Actelion’s 2009 financial results
19 February 2010
US FDA advisory panel back approval of Recordati’s Carbaglu and new use for Actelion’s Zavesca
15 January 2010
2008 profit doubles for Actelion on 2007 costs
2 March 2009
Actelion's Zavesca cleared for NPC
9 February 2009
CHMP OKs Actelion's Zavesca for NPC
15 January 2009
Actelion recovers from poor first quarter
4 August 2008
Actelion's 2007 profit falls 47% on costs
3 March 2008
Actelion drops EMEA indication extension for Zavesca
3 March 2008
Actelion's FY 2007 net revenues beat forecasts
28 January 2008
France's LEEM launches orphan drug campaign
2 July 2007
Actelion's 1st-qtr 2007 loss deepens 179%
30 April 2007
Actelion sees 1st-half sales of 437.1M SwFr
31 July 2006
Actelion beats 1st-qtr 2006 forecasts
1 May 2006
Actelion's R&D day: eight compounds in pipeline
19 September 2005
Actelion ups guidance on good 1st half
8 August 2005
Actelion sees 1sr-qtr net profit leap 52%
26 April 2005
Actelion posts 1st-half sales growth of 63%
2 August 2004
Actelion and Celltech extend Zavesca deal
21 June 2004
Actelion sees record revenues for 1st-qtr
3 May 2004
Actelion's target price bumped up
2 February 2004
New Chemical Entities in 2003
19 January 2004
Zavesca capsules available in the USA
5 January 2004
Actelion aiming high as profits grow
3 November 2003
Celltech's Zavesca cleared by FDA
11 August 2003
Zavesca approved in Israel for Gaucher disease
23 June 2003
OGS files new data on Zavesca with FDA
31 March 2003
Cambridge Antibody/Oxford GlycoSciences merger "positive"
3 February 2003
Actelion's Tracleer ahead of forecasts
3 February 2003
OGS says Teva files Zavesca in Israel
27 January 2003
Positive CPMP ruling on OGS' Zavesca
5 August 2002
Showing 1-40 of 40 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
